Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 2/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31482443 | 0.97 | ADORA2B (0.81) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL11699832 | 0.95 | ADORA2B (0.78) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL10394216 | 0.95 | ADORA2B (0.78) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL11702145 | 0.95 | ADORA2B (0.78) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL11701929 | 0.95 | ADORA2B (0.78) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL16120979 | 0.92 | ADORA2B (0.85) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL16120975 | 0.92 | ADORA2B (0.88) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL8443037 | 0.90 | ADORA2B (0.77) | ADORA2BADORA2ALMNAMAPTPDE4A | |
| SCHEMBL16120983 | 0.90 | ADORA2B (0.85) | ADORA2BADORA2ALMNAMAPTMAPK1 | |
| SCHEMBL16121000 | 0.90 | ADORA2B (0.85) | ADORA2BADORA2ALMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119812357-A | Membrane electrode of oxyhydrogen fuel cell and oxyhydrogen fuel cell comprising same | 北京大学 | 2025-04-11 | — | — | CN | claimed |
| EP-3197458-B1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOATTRACTANT CYTOKINES | GREENPHARMA S A (FR) | 2021-03-31 | — | — | EP | claimed |
| US-20170296547-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES | UNIVERSITE DE STRASBOURG (FR) | 2017-10-19 | — | — | US | claimed |
| CN-119812357-A | Membrane electrode of oxyhydrogen fuel cell and oxyhydrogen fuel cell comprising same | 北京大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-115850279-B | Theophylline derived spontaneous combustion ionic salt and preparation method thereof | 哈尔滨工业大学（深圳） | 2024-11-15 | — | — | CN | disclosed |
| CN-115850279-A | Theophylline derived autoignition ionic salt and preparation method thereof | 哈尔滨工业大学（深圳） | 2023-03-28 | — | — | CN | disclosed |
| EP-3197458-B1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOATTRACTANT CYTOKINES | GREENPHARMA S A (FR) | 2021-03-31 | — | — | EP | disclosed |
| EP-3197458-B1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOATTRACTANT CYTOKINES | GREENPHARMA S A (FR) | 2021-03-31 | — | — | EP | disclosed |
| US-10828309-B2 | Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines | GREENPHARMA (FR) | 2020-11-10 | — | — | US | disclosed |
| US-10828309-B2 | Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines | GREENPHARMA (FR) | 2020-11-10 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-2120871-B1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2014-11-26 | — | — | EP | disclosed |
| CN-101636148-B | Linker-based lecithin microemulsion delivery vehicle | ACOSTA-ZARA EDGAR JOEL | 2014-02-26 | — | — | CN | disclosed |
| US-20100303805-A1 | IDENTIFICATION OF SMALL MOLECULES RECOGNIZED BY ANTIBODIES IN SUBJECTS WITH NEURODEGENERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-12-02 | — | — | US | disclosed |
| CN-101636148-A | Linker-based lecithin microemulsion delivery vehicle | JOEL ACOSTA-ZARA EDGAR | 2010-01-27 | — | — | CN | disclosed |
| EP-2120871-A1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | Acosta-Zara, Edgar, Joel (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008070961-A1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139392-A1 | Linker-Based Lecithin Microemulsion Delivery Vehicles | ACOSTA-ZARA EDGAR JOEL | 2008-06-12 | — | — | US | disclosed |
| US-7160920-B2 | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders | NITROMED, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-5550041-A | PRODUCING 3-METHYL-7-ALKYLXANTHINE BY CULTIVATING PSEUDOMONAS TRANSFORMED TO PRODUCE CAFFEINE DEMETHYLASE IN NUTRIENT MEDIUM CONTAINING 1,3-DIMETHYL-7-ALKYLXANTHINE | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303805-A1 | IDENTIFICATION OF SMALL MOLECULES RECOGNIZED BY ANTIBODIES IN SUBJECTS WITH NEURODEGENERATIVE DISEASES | PARK7, CLN6, NLN | ADORA2B 3592/4885ADORA2A 3713/4885LMNA 4361/4885 |
| US-20170296547-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES | CCL2, CCL11, CCL5 | ADORA2B 1065/4885ADORA2A 762/4885LMNA 3426/4885 |
| US-10828309-B2 | Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines | CCL2, CCL11, CCL5 | ADORA2B 1065/4885ADORA2A 762/4885LMNA 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.